Treatment with a commonly used drug slows the decline in lung function in patients with chronic obstructive pulmonary disease (COPD), according to results from the TORCH (TOwards a Revolution in COPD Health) new study.
The study of 6,112 patients from 42 countries found that those treated with salmeterol/fluticasone propionate (Advair) had a slower rate of lung function decline compared with patients receiving a placebo over three years (39 vs. 55 milliliters per year).
Patients who received either the long-acting beta2-agonist salmeterol (Serevent) or the inhaled corticosteroid fluticasone propionate (Flovent) alone also had less of a decline in lung function than those receiving the placebo, but the decline was smaller than with the combined salmeterol/fluticasone propionate treatment.
The study also found that patients with a low body mass index (BMI) lose more lung function than those with a higher BMI. (read more at ScienceDaily)…
Suggested Reading by XLPharmacy Canada
BLU Electronic Cigarettes
Blu gives you much much more!
About Me
- Online Village Cafe for BLU
- We at Online Village Cafe understand how difficult it can be to find what you are looking for in the ever changing world of shopping. We are here to review popular items on the market today and give our opinions, coupons, advice on products we purchase, try, and then comment on for you. Sometimes reading others opinions before you buy is the best way to test a product without taking on the expense yourself. We also post a great deal of health articles for you to read! So be sure to stop in often and see what we have reviewed lately or what new health article we have posted!
